Siemens to Create Companion Diagnostic Test for In-Development Janssen Heart Failure Drug

  Siemens to Create Companion Diagnostic Test for In-Development Janssen Heart
  Failure Drug

Business Wire

TARRYTOWN, N.Y. -- June 17, 2013

Today, Siemens Healthcare Diagnostics announces its entrance into a
collaboration with Janssen Pharmaceutica NV to design, develop and
commercialize a companion diagnostic test associated with an early-stage
compound being developed by Janssen. This compound targets autoantibodies
directed against the human β1-adrenergic receptor (β1-AR) that may contribute
to the development of heart failure.

Under the agreement, Siemens will work with Janssen to design
immunoassay-basedcompanion diagnostic tests for use in Janssen's clinical
studies.TheSiemens Clinical
Laboratory(SCL),aninnovativeandhigh-complexity testing
laboratorydesignedto advance personalized medicine,will develop the
clinical trial assay that will be used in Janssen’s clinical trials. In
parallel, Siemens will develop and validate an in vitro diagnostic test as a
companion diagnostic for the Janssen therapeutic product. The companion
diagnostic test will be broadly commercialized on Siemens' central laboratory
automated immunoassay systems.

Heart failure is generally a progressive disease characterized by the heart
muscle’s inability to adequately pump oxygenated blood through the body. An
estimated 23 million people around the world have been diagnosed with heart
failure, a number that is projected to increase.¹ For most causes of heart
failure, there is no known cure.

“Our relationship with Janssen marks an important next step in Siemens’
personalized medicine strategy,” said Michael Reitermann, CEO, Siemens
Healthcare Diagnostics. “As a leading clinical diagnostics company, with the
tools and technologies to help define the future of patient care, we are
looking forward to collaborating with Janssen and extending their position in
cardiac therapies.”

¹Cleland JG, Khand A, Clark A. The heart failure epidemic: exactly how big is
it? Eur Heart J 2001;22:623-6.

Launched in November 2011, “Agenda 2013” is the initiative of the Siemens
Healthcare Sector to further strengthenits innovative power and
competitiveness. Specific measures, which will be implemented by the end of
2013, have been defined in four fields of action: innovation, competitiveness,
regional footprint, and people development.

The Siemens Healthcare Sector is one of the world's largest suppliers to the
healthcare industry and a trendsetter in medical imaging, laboratory
diagnostics, medical information technology and hearing aids. Siemens offers
its customers products and solutions for the entire range of patient care from
a single source – from prevention and early detection to diagnosis, and on to
treatment and aftercare. By optimizing clinical workflows for the most common
diseases, Siemens also makes healthcare faster, better and more
cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and
operates around the world. In fiscal year 2012 (to September 30), the Sector
posted revenue of 13.6 billion euros and profit of around 1.8 billion euros.
For further information please visit:


Siemens Healthcare Media Relations
Gian Sachdev, 508-660-4721